A Phase 3 interventional study of IGIV3I Grifols in Immune (Idiopathic) Thrombocytopenic Purpura, sponsored by Instituto Grifols, S.A.. Completed at 7 sites in 3 countries. Open to participants aged 18 Years to 82 Years. Per ClinicalTrials.gov, last updated 2016-02-08.
Sponsored by Instituto Grifols, S.A. (part of Grifols) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine whether IGIV3I Grifols 10% is effective in the treatment of immune thrombocytopenic purpura.
To determine if IGIV3I Grifols 10% is a consistently effective treatment in patients diagnosed with immune thrombocytopenic purpura with respect to:
To determine if IGIV3I Grifols 10% is safe with respect to:
Nature, severity and frequency of adverse reactions during and after infusions by percentage of subjects and percentage of infusions.
32 studies on the registry are indexed under Purpura, Thrombocytopenic; 6 are open to participants now.
This study's enrollment of 18 is below the median of 54 across 22 interventional studies indexed under Purpura, Thrombocytopenic.
Browse Purpura, Thrombocytopenic studies →Instituto Grifols, S.A. is the lead sponsor of 24 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have confirmed diagnosis of chronic ITP and fulfil all the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open label, non-randomized treatment group with IGIV3I Grifols Each patient received a total dose of 2 g/kg IGIV3I Grifols, given intravenously over either 2 days or 5 days in divided doses.
Biological: IGIV3I Grifols
Immune Globulin Intravenous (Human)
Also known as: IGIV
Responder Patients
The primary efficacy endpoint was the proportion of patients who reached a platelet count ≥ 50x10\^9/L.
Time frame: At any time during the study period (The platelet count was measured at Days 1-6, 10, 14. 21, 30, 60, 90).
Maximum Platelet Level Reached During the Follow-up Period
Platelet count was measured at various time points in the follow-up period after infusion.
Time frame: During the follow-up period (time points: Days 6, 10, 14, 21, 30, 60, 90 post-first infusion day [Day 1])
Time to Reach Platelet Count ≥ 50x10^9/L (≤ Days)
The time taken for the platelet count to reach ≥ 50x10\^9/L from first dose
Time frame: At any time during the study period (time points: Days 1-6, 10, 14, 21, 30, 60, 90 post-first infusion day [Day 1])
Length of Time Platelet Count Remains ≥ 50x10^9/L (≥ Days)
Length of time platelet count remained ≥ 50x10\^9/L from first dose (Day 1)
Time frame: At any time during the study period (up to 3 months [90 days])
Regression of Hemorrhages.
Percentage of subjects with regression of hemorrhages of Types 1 to 3: * Type 0: Patients without symptoms of bleeding at the first infusion continue without presenting spontaneous bleeding * Type 1: Patients with bleeding symptoms at the first infusion had a reduction of the size of large ecchymoses, and no spontaneous appearance of new ecchymoses * Type 2: Patients with bleeding symptoms at the first infusion had a decrease in the number of cutaneous petechiae, or the extent of the affected area of the body decreased * Type 3: Patients had active mucosal bleedings at the first infusion, these episodes stopped without re-bleeding, and there was no occurrence of new spontaneous mucosal hemorrhages (e.g., gingival bleeding, epistaxis)
Time frame: First 10 to14 days since the first infusion day (Day 1)
Frequency of Adverse Reactions During and After Infusions by Percentage of Patients
All adverse events (AEs) are tabulated and summarized. The incidence, severity, and causal relationship of the AEs to IGIV3I Grifols are presented by system organ class after medical coding according to the version 15.0 of Medical Dictionary for Regulatory Activities (MedDRA). The frequency of patients with at least one AE and adverse drug reactions are estimated.
Time frame: At any time during the study period (from patient's signature of the informed consent form until 3 months of follow-up)
Frequency of Adverse Reactions During and After Infusions by Percentage of Infusions
All adverse events (AEs) are tabulated and summarized. The incidence, severity, and causal relationship of the AEs to IGIV3I Grifols are presented by system organ class after medical coding according to the version 15.0 of Medical Dictionary for Regulatory Activities (MedDRA). The frequency of infusions associated with at least one AE and adverse drug reactions are estimated.
Time frame: At any time during the study period (from patient's signature of the informed consent form until 3 months of follow-up)
Changes in Vital Signs and Clinically Relevant Changes in Laboratory Parameters After the Infusions, Including Renal Function (Creatinine Levels)
Laboratory parameters at each treatment day and visit are summarized by patient. Results were marked as normal/abnormal (whether the result is below, within or above the respective reference range) and relevant/irrelevant (as determined by the investigator). The number of abnormal values considered clinically relevant changes (based on the investigator's judgment) was listed.
Time frame: At any time during the study period (from patient's signature of the informed consent form until 3 months of follow-up)
Viral Safety Through the Investigation of Patients Virology Status (Hepatitis A Virus [HA
The results of HIV-1 and -2 antibodies, HCV antibody, HBsAg, HBV antibodies, HAV antibodies, HIV nucleic acid amplification test \[NAT\], and HCV NAT on Day 1, Day 14, and at Month 1, Month 2 and Month 3 were recorded for several of these markers (as appropriate). A comparison of negative viral markers on Day 1 and Month 3 was performed
Time frame: At any time during the study period (from patient's signature of the informed consent form until 3 months of follow-up)
| Milestone | 1 Treatment Group With IGIV3I |
|---|---|
| Started | 18 |
| Completed | 18 |
| Not completed | 0 |
The primary efficacy endpoint was the proportion of patients who reached a platelet count ≥ 50x10\^9/L.
| percentage of subjects | 1 Treatment Group With IGIV3I |
|---|---|
| Responder Patients | 72.2 (50.2 to 88.4) |
Platelet count was measured at various time points in the follow-up period after infusion.
| platelets x 10^-9/L | 1 Treatment Group With IGIV3I |
|---|---|
| Maximum Platelet Level Reached During the Follow-up Period | 146.0 (71.0 to 763.0) |
The time taken for the platelet count to reach ≥ 50x10\^9/L from first dose
| days | 1 Treatment Group With IGIV3I |
|---|---|
| Time to Reach Platelet Count ≥ 50x10^9/L (≤ Days) | 2 (0 to 5) |
Length of time platelet count remained ≥ 50x10\^9/L from first dose (Day 1)
| days | 1 Treatment Group With IGIV3I |
|---|---|
| Length of Time Platelet Count Remains ≥ 50x10^9/L (≥ Days) | 9 (3 to 61) |
Percentage of subjects with regression of hemorrhages of Types 1 to 3: * Type 0: Patients without symptoms of bleeding at the first infusion continue without presenting spontaneous bleeding * Type 1: Patients with bleeding symptoms at the first infusion had a reduction of the size of large ecchymoses, and no spontaneous appearance of new ecchymoses * Type 2: Patients with bleeding symptoms at the first infusion had a decrease in the number of cutaneous petechiae, or the extent of the affected area of the body decreased * Type 3: Patients had active mucosal bleedings at the first infusion, these episodes stopped without re-bleeding, and there was no occurrence of new spontaneous mucosal hemorrhages (e.g., gingival bleeding, epistaxis)
| percentage of subjects | 1 Treatment Group With IGIV3I |
|---|---|
| Regression of Hemorrhages. | 83.3 (62.3 to 95.3) |
All adverse events (AEs) are tabulated and summarized. The incidence, severity, and causal relationship of the AEs to IGIV3I Grifols are presented by system organ class after medical coding according to the version 15.0 of Medical Dictionary for Regulatory Activities (MedDRA). The frequency of patients with at least one AE and adverse drug reactions are estimated.
| percentage of patients | 1 Treatment Group With IGIV3I |
|---|---|
| Frequency of patients with AEs | 88.9 |
| Frequency of patients with adverse drug reactions | 38.9 |
All adverse events (AEs) are tabulated and summarized. The incidence, severity, and causal relationship of the AEs to IGIV3I Grifols are presented by system organ class after medical coding according to the version 15.0 of Medical Dictionary for Regulatory Activities (MedDRA). The frequency of infusions associated with at least one AE and adverse drug reactions are estimated.
| percentage of infusions | 1 Treatment Group With IGIV3I Grifols |
|---|---|
| Frequency of infusions with adverse events | 26.3 |
| Frequency of infusions with adverse drug reactions | 24.6 |
Laboratory parameters at each treatment day and visit are summarized by patient. Results were marked as normal/abnormal (whether the result is below, within or above the respective reference range) and relevant/irrelevant (as determined by the investigator). The number of abnormal values considered clinically relevant changes (based on the investigator's judgment) was listed.
| participants | 1 Treatment Group With IGIV3I Grifols |
|---|---|
| Clinically relevant changes in vital signs | 0 |
| Clinically relevant changes in lab parameters | 7 |
The results of HIV-1 and -2 antibodies, HCV antibody, HBsAg, HBV antibodies, HAV antibodies, HIV nucleic acid amplification test \[NAT\], and HCV NAT on Day 1, Day 14, and at Month 1, Month 2 and Month 3 were recorded for several of these markers (as appropriate). A comparison of negative viral markers on Day 1 and Month 3 was performed
| seroconversions | 1 Treatment Group With IGIV3I |
|---|---|
| Viral Safety Through the Investigation of Patients Virology Status (Hepatitis A Virus [HA | 0 |
Collected over 3 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 1 Treatment Group With IGIV3I Grifols | — | 2/18 (11.1%) | 12/18 (66.7%) |
| Event | 1 Treatment Group With IGIV3I Grifols |
|---|---|
| ThrombosisVascular disorders | 1/18 |
| Haemoglobin decreasedInvestigations | 1/18 |
| LeukopeniaBlood and lymphatic system disorders | 1/18 |
| Event | 1 Treatment Group With IGIV3I Grifols |
|---|---|
| PetechiaeSkin and subcutaneous tissue disorders | 12/18 |
| EcchymosisSkin and subcutaneous tissue disorders | 8/18 |
| HeadacheNervous system disorders | 7/18 |
| PyrexiaGeneral disorders | 4/18 |
| RashSkin and subcutaneous tissue disorders | 2/18 |
| ChillsGeneral disorders | 2/18 |
| Gingival bleedingGastrointestinal disorders | 2/18 |
| HypertensionVascular disorders | 2/18 |
| Palmar erythemaSkin and subcutaneous tissue disorders | 1/18 |
| FatigueGeneral disorders | 1/18 |
| Age, Categorical(Participants) | 1 Treatment Group With IGIV3I |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 16 |
| >=65 years | 2 |
| Age, Continuous(years) | 1 Treatment Group With IGIV3I |
|---|---|
| Median | 43 (20 to 77) |
| Sex: Female, Male(Participants) | 1 Treatment Group With IGIV3I |
|---|---|
| Female | 12 |
| Male | 6 |
| Race (NIH/OMB)(Participants) | 1 Treatment Group With IGIV3I |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 18 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | 1 Treatment Group With IGIV3I |
|---|---|
| Russian Federation | 12 |
| United Kingdom | 2 |
| Spain | 4 |
| Subjects with medical history of splenectomy(participants) | 1 Treatment Group With IGIV3I |
|---|---|
| Yes | 9 |
| No | 9 |
| Subjects with haemorrhagic history(participants) | 1 Treatment Group With IGIV3I |
|---|---|
| Yes | 13 |
| No | 5 |
| Platelet count(platelets x 10^-9/L) | 1 Treatment Group With IGIV3I |
|---|---|
| Median | 8.5 (3.0 to 36.0) |
The record gives a start of Feb 2008, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2016, 2 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Immunoglobulins, Intravenous